Skip to main content
Fig. 2 | Journal of Neuroinflammation

Fig. 2

From: The NLRP3 inflammasome: an emerging therapeutic target for chronic pain

Fig. 2

The chemical structure of the specific NLRP3 inflammasome antagonist MCC950. MCC950, a sulfonylurea molecule, was first discovered by Matthew Cooper et al., with original name CRID3, and then renamed MCC950 for “Matthew Cooper compound 950” [28]. MCC950 is a potent, selective, and small-molecule inhibitor of NLRP3 working at nM concentration. It specifically inhibited NLRP3 activation but not other inflammasome activation, including NLRP1, NLRC4, or AIM. Recent evidence suggests that the mechanism of MCC950 involves the closing of the open conformation of active NLRP3 [29].

Back to article page
\